Prostate Cancer Biomarker Panel

Example 8

Serum samples from patients were tested with the FLNA IPMRM, as described above, using the anti-FLNA monoclonal antibodies of the invention. The results were combined with data on age, PSA, and Gleason score and subjected to regression modelling. As shown in FIG. 10, a Prostate Cancer Biomarker Panel consisting of biomarkers FLNA, FLNB, age and PSA improved the classification of prediction of prostate cancer over PSA alone (AUC=0.64, [0.59, 0.69], vs 0.58).

Samples of patient serum were also analyzed for the biomarkers FLNA, keratin 19 (KRT19) and age combined, versus PSA alone. FIG. 11 shows that the biomarkers FLNA, KRT19 and age have improved classification of prediction between patients with benign prostatic hyperplasia versus prostate cancer over PSA alone (AUC=0.70 [0.60, 0.80], vs 0.58).

Free full text: Click here

US11866487B2. Filamin A binding proteins and uses thereof (2024-01-09). BPGbio, Inc. [US]. Inventors: Wenfang Sybil Wu [US], Shobha Ravipaty [US], Tracey Friss [US], Viatcheslav R. Akmaev [US], Nikunj Narendra Tanna [US].

Patent 2024

Anti antibodies Benign prostatic hyperplasia Biomarkers Cancer biomarker Keratin 19 Monoclonal antibodies Patients Prostate Prostate cancer Serum

Top 5 similar protocols

Variable analysis

independent variables

Keratin 19 (KRT19)

dependent variables

Prediction of prostate cancer
Classification of prediction between patients with benign prostatic hyperplasia versus prostate cancer

control variables

Serum samples from patients

controls

PSA alone

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!